Results 261 to 270 of about 4,376,584 (354)

Ulcerated Gottron's papules in anti‐MDA5 dermatomyositis

open access: yes
Arthritis &Rheumatology, Accepted Article.
Philipp Jud, Monica D'Orazio
wiley   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit   +6 more
wiley   +1 more source

The role of inflammation in the pathogenesis of pulmonary fibrosis: mechanisms and treatment implications. [PDF]

open access: yesEur Respir J
Nazemi N   +8 more
europepmc   +1 more source

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong   +10 more
wiley   +1 more source

Inter-species transmission of <i>Chlamydophila psittaci</i> from broiler chickens to ducks, turkeys, pigeons, and quails: an experimental study. [PDF]

open access: yesFront Vet Sci
Hegazy AME   +9 more
europepmc   +1 more source

Correction: Understanding emotional and practical challenges of initiating oxygen therapy in pulmonary fibrosis: insights from a patient-centered survey

open access: yesBMC Pulmonary Medicine
Marjolein Drent   +4 more
doaj   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu   +3 more
wiley   +1 more source

Impact of Severe COVID-19 on Interstitial Lung Disease in Autoimmune Systemic Diseases. [PDF]

open access: yesRespirol Case Rep
Ferri C   +21 more
europepmc   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi   +9 more
wiley   +1 more source

Increased calcification by erythrophagocytosis in aortic valvular interstitial cells

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1469-1473, April 2025.
Abstract Background Calcific aortic valve disease (CAVD) progresses over time to severe aortic stenosis and eventually heart failure. Recent evidence indicates that intraleaflet haemorrhage (ILH) strongly promotes CAVD progression. However, it remains poorly understood how it mechanistically contributes to valvular calcification.
Zihan Qin   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy